Corvus Pharmaceuticals (CRVS)
(Delayed Data from NSDQ)
$2.17 USD
-0.06 (-2.69%)
Updated Jul 24, 2024 04:00 PM ET
After-Market: $2.18 +0.01 (0.46%) 7:58 PM ET
3-Hold of 5 3
D Value D Growth D Momentum F VGM
Brokerage Reports
Corvus Pharmaceuticals, Inc. [CRVS]
Reports for Purchase
Showing records 81 - 100 ( 154 total )
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Market Shudders But We See Names to Outperform.
Provider: H.C. Wainwright & Co., Inc.
Analyst: Research Department
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Consider Reading Vol. 7: Observations From Treatment Responsive Cancer Patients
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Q4 Financials; 2020 Focus on Pipeline Advancement
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Developing Next-Generation Cancer Immunotherapy; Initiate With Buy and a $10 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: RAMAKANTH S
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
4Q19: Confident That Programs Are Positioned For Success In 2020
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
We Highlight Additional Biotech Companies Attending the 2020 Conference
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Consider Reading Vol.6: Nonredundant Adenosine Blocking - Implications for CRVS
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Ph 1b/2 Prostate Cancer Update for Ciforadenant at ASCO GU
Provider: WEDBUSH SECURITIES INC.
Analyst: DRISCOLL R
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Adenosine Blockade And Anti-PD-L1 Combo Regresses Cancer. Is That Enough?
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
"Consider Reading" Vol. 5: B-Cells May Aid IO Responses - Implications for CRVS
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
"Consider Reading" Vol. 2. CD73 Might Be a Good IO Target. Could CRVS Benefit?
Provider: Roth Capital Partners, Inc.
Analyst: BUTLER T
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Corvus Pharmaceuticals, Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D